Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Afraxis Hopes Experimental Fragile X Drug Could Apply To Other CNS Diseases

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech believes that inactivation of p21-activated kinase may address underlying cause of Fragile X syndrome.

You may also be interested in...



Afraxis Inc.

Afraxis Inc. is developing p21-activated kinase (PAK) inhibitors, initially for Fragile X syndrome, a genetic condition involving changes in the X chromosome that can lead to cognitive impairment and autism-like behaviors. The start-up thinks treatment of this orphan indication may be a gateway to developing PAK inhibitors for closely related conditions, such as autism and other central nervous system disorders like Alzheimer's disease and schizophrenia.

Lilly To Cease Development Of Alzheimer's Drug: A Blow To The Amyloid Hypothesis?

Eli Lilly said August 17 it would halt development of its Phase III Alzheimer's drug candidate semagacestat, casting some doubt on the efficacy of novel gamma secretase inhibitor drugs and slowing Lilly's late-stage pipeline as the company struggles to replace future revenues that will be lost to drugs going off patent

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel